Abeona Therapeutics Inc (CH:PCJ)
NASDAQ:PCJ
PCJ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Commercial Revenue TractionSustained early commercial receipts and a meaningful TTM revenue rebound indicate the company is moving beyond purely clinical-stage economics. Durable revenue growth and solid gross margins help reduce reliance on financing, support reinvestment in operations, and make future scaling and payer negotiations structurally easier over the next 2–6 months.
Broad Payer Coverage & ReimbursementHigh published commercial coverage and a permanent J-code materially lower reimbursement friction and administrative barriers. This structural access supports predictable billing, reduces denial risk, and improves the odds that demand converts to reimbursed revenue as the QTC network scales over the medium term.
Manufacturing And Clinical ExecutionConsistent, fast manufacturing turnarounds and no reported harvest failures demonstrate operational reliability critical for autologous gene therapy. Combined with an expanding QTC footprint, this durable execution capability reduces supply risk, supports predictable throughput per center, and underpins sustainable commercial scale-up over several months.
Bears Say
Persistent Cash BurnSubstantial negative operating and free cash flows mean the business remains reliant on external funding. Even with improving revenue, continued cash burn increases dilution and constrains strategic flexibility, making sustained investment or unexpected setbacks potentially damaging to operations and timelines over the next 2–6 months.
Elevated Operating ExpensesRapid SG&A growth and higher operating costs can outpace nascent revenue, delaying break-even and worsening cash burn. Structural commercial costs (personnel, field teams, engineering runs) may be sustained as the company builds market presence, pressuring margins and cash flow during the scale-up phase.
Operational & Reimbursement Timing RisksMulti-month onboarding and lengthy payer approvals create persistent timing variability in patient throughput and revenue recognition. These structural delays complicate forecasting, slow path to steady-state per-center volumes, and can prolong the period before fixed commercial costs are absorbed, raising execution risk.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Abeona Therapeutics Inc’s market cap?
Abeona Therapeutics Inc’s market cap is CHF255.88M.
When is Abeona Therapeutics Inc’s upcoming earnings report date?
Abeona Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Abeona Therapeutics Inc’s earnings last quarter?
Abeona Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.234 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.027.
Is Abeona Therapeutics Inc overvalued?
According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued.
Does Abeona Therapeutics Inc pay dividends?
Abeona Therapeutics Inc does not currently pay dividends.
What is Abeona Therapeutics Inc’s EPS estimate?
Abeona Therapeutics Inc’s EPS estimate is -0.17.
How many shares outstanding does Abeona Therapeutics Inc have?
Currently, no data Available
What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?
Abeona Therapeutics Inc reported an EPS of -$0.234 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Abeona Therapeutics Inc?
Currently, no hedge funds are holding shares in CH:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF15.14 (― Downside)
CHF15.14 (― Downside)
Insider Transactions
Sold Shares
Worth CHF56.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.77%
12-Months-Change
Fundamentals
Return on Equity
41.40%
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
PCJ Company Deck
PCJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.View all CH:PCJ earnings summariesPCJ Stock 12 Month Forecast
Average Price Target
$15.14
Options Prices
Currently, No data available
---